MedTrace Logo

Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer

NCT01898065 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-11-09

No results posted yet for this study

Summary

With functional imaging development, it becomes possible to increase radiation dose to radioresistant areas (located inside tumor volume) using radiotherapy dose-painting. This strategy is particularly suitable for prostate cancer where tumor hypoxia plays a major role in the resistance of these tumors to radiation.

In order to develop intratumoral hypoxia targeting by radiotherapy dose-painting areas, we should characterize changes in hypoxia before treatment and during radiotherapy.

* If hypoxia does not change during radiotherapy, radiotherapy dose-painting strategy by an "integrated" boost is performed.
* If hypoxia varied (increasing or incomplete regression), a "final" boost strategy of radiotherapy dose-painting(IMRT, stereotactic brachytherapy or high dose rate) after a first fractionated IMRT could be considered.

This study should show that PET imaging with fluoromisonidazole (18F-MISO) is an available tool to physicians in assessing tumor hypoxia.

Conditions

  • Prostate Adenocarcinoma

Interventions

DRUG

18-F-MISO

PET scan with the 18 Fluoro Misonidazole

Sponsors & Collaborators

  • Poitiers University Hospital

    collaborator OTHER

  • IASON Gmbh, Feldkirchner strasse 4, 8054 Graz-Seiesberg AUSTRIA

    collaborator UNKNOWN

  • Cyclopharma

    collaborator INDUSTRY

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • SUPIOT Stéphane, MD · ICO René Gauducheau

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-11-30
Completion
2015-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01898065 on ClinicalTrials.gov